Chimeric Antigen Receptor Modified T Cells Infusion
Platinum-Resistant Ovarian Carcinoma
City of Hope Medical CenterCell therapyPhase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 28/ 100
- Competitive Position
- 89/ 100
Competitive context
11 Active assets in the Platinum-Resistant Ovarian Carcinoma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Durvalumab AGO Research GmbH | Phase 2 | BB |
Guadecitabine National Cancer Institute (NCI) | Phase 2 | BB |
Zofran Mayo Clinic | Phase 2 | B |
Oncolytic Measles Virus Encoding Thyroidal Sodium Iodide Symporter Mayo Clinic | Phase 2 | B |
Irinotecan Sucrosofate Northwestern University | Phase 2 | B |
View all 17 →
Same molecule, other indications
Chimeric Antigen Receptor Modified T Cells Infusion is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →